There is thus an urgent need to identify novel targeted therapeutic combinations to improve the efficacy of Neratinib by abrogating the aberrant expression or activation of HER2 in the treatment of HER2+ or HER2-mutated breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.